AARTIPHARM Q2 FY27 Results & Earnings Analysis
Sentiment: Good (Confidence: high)
Earnings Summary
Aarti Pharmalabs delivered strong Q2 FY27 results with revenue up 47% YoY to INR613 crores, EBITDA up 84% YoY to INR136 crores, and PAT of INR66 crores (2.75x YoY). EBITDA margin expanded to 22.2% from 17.7%. Growth was driven by CDMO (almost doubled QoQ), Xanthine volume and price gains, and API recovery. Management maintains 40-50% CDMO growth guidance and targets INR1,000 crores CDMO revenue in 2-3 years. Capacity expansions (Xanthine, Atali) are on track for full utilization by H2 FY27. Working capital increased due to higher sales and CDMO inventory build, but management considers it manageable. Overall, the call conveyed a positive outlook with confidence in achieving long-term growth targets.
Management Tone
- Prepared Remarks: Good — Prepared remarks highlighted strong financial performance with record revenue, significant EBITDA and PAT growth, and strategic progress on capacity expansions and CDMO pipeline. Management conveyed confidence in the business trajectory.
- Q&A Session: Good — Analysts asked detailed questions on capacity utilization, margin drivers, working capital, and growth guidance. Management provided specific, quantified responses with transparency on both positives and challenges.
Revenue Growth Drivers
- Strong CDMO revenue growth (nearly doubled QoQ)
- Xanthine volume ramp-up with expanded capacity
- Xanthine price realization improvement
Growth vs Margin Focus
Management is pursuing revenue growth through CDMO expansion and capacity additions while also improving margins via favorable mix and pricing. They aim to balance both, with absolute gross margins increasing as more CDMO business is done.
About Aarti Pharmalabs Limited
Aarti Pharmalabs Limited (AARTIPHARM) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.